H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $185 from $180 and keeps a Buy rating on the shares after narrow top-line beat and bottom-line miss in Q3. However, the positive operating cash flow “signals progress towards profitability,” the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley
- Axsome Therapeutics price target raised to $178 from $176 at BofA
- Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion